Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168901 | 0.90 | MAPT (0.51) | AGTR1AGTR2VDRNR1H4RAB9A | |
| SCHEMBL6169148 | 0.87 | AGTR1 (0.52) | AGTR1AGTR2VDRNR1H4PPARG | |
| SCHEMBL6168952 | 0.83 | GLP1R (0.51) | AGTR1AGTR2NR4A2RAB9APPARG | |
| SCHEMBL1178905 | 0.83 | AGTR2 (0.49) | AGTR1AGTR2VDRNR1H4RAB9A | |
| Ammonia Solution, Strong SCHEMBL6170533 | 0.82 | AGTR2 (0.49) | AGTR1AGTR2VDRNR1H4RAB9A | |
| SCHEMBL6167846 | 0.80 | NR4A2 (0.52) | NR4A2VDRNR1H4RAB9APPARG | |
| SCHEMBL6167804 | 0.79 | PPARG (0.66) | AGTR1AGTR2PPARG | |
| SCHEMBL6170372 | 0.77 | MAPT (0.50) | AGTR1AGTR2PPARGALOX5APMAOB | |
| SCHEMBL6170337 | 0.76 | MAPT (0.55) | RAB9AALOX5APMAOB | |
| SCHEMBL9200654 | 0.74 | AGTR1 (1.00) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | AGTR1 4001/4885AGTR2 3926/4885NR4A2 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.